Fungal peritonitis in patients on peritoneal dialysis: twenty five years of experience in a teaching hospital in Argentina.
Fungal peritonitis is a rare but serious complication of peritoneal dialysis. The aim of this study was to analyze peritonitis rates, associated factors, clinical course, microbiological aspects, therapeutic regimens, and outcome of patients with fungal peritonitis in the dialysis center of a teaching hospital over the last 25 years. A hundred and eighty three episodes of peritonitis were detected and microbiologically documented in 57 patients. Fungi were identified in eight episodes (4.37%) occurring in seven female patients. The fungal peritonitis rate was 0.06 episodes/patient-year. Gram and Giemsa stains were positive in five out of eight dialysate fluids. The causative microorganisms were: Candida albicans in five episodes, and Candida parapsilosis, Candida glabrata, and Neosartorya hiratsukae in the remaining three. Antibiotics were administered to all but one patient, within 3 months before fungal peritonitis was detected. All patients required hospitalization, and antifungal therapy was administered in all episodes. The Tenckhoff catheter was removed in seven out of eight fungal peritonitis. All patients recovered from the fungal episodes. In the group of patients studied, it is concluded that recent exposure to antibiotics and female sex, were strongly associated with the development of fungal peritonitis by yeasts. The peritonitis caused by the environmental filamentous fungus did not require antibiotic pressure. Direct microscopy of the dialysate pellet was extremely useful for the prompt management of the fungal episode. Fungal peritonitis preceded by multiple episodes of bacterial peritonitis always determined the definitive dropout of the patient from the peritoneal dialysis program. Patients with de novo yeast-related peritonitis could continue on the program.
Predari
S C
SC
Department of Microbiology, Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Argentina. scpredari@lanari.fmed.uba.ar
de Paulis
A N
AN
Verón
D
D
Zucchini
A
A
Santoianni
J E
JE
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D001118:Argentina / Q000453:epidemiology; D001203:Ascomycota; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy; D002177:Candidiasis / Q000453:epidemiology* / Q000209:etiology; D002408:Catheters, Indwelling / Q000009:adverse effects*; D003428:Cross Infection / Q000453:epidemiology* / Q000209:etiology / Q000382:microbiology; D004866:Equipment Contamination; D005260:Female; D006784:Hospitals, Teaching / Q000706:statistics & numerical data; D006801:Humans; D008875:Middle Aged; D009181:Mycoses / Q000453:epidemiology / Q000209:etiology; D010530:Peritoneal Dialysis / Q000009:adverse effects* / Q000295:instrumentation; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects / Q000295:instrumentation; D010538:Peritonitis / Q000453:epidemiology* / Q000209:etiology / Q000382:microbiology; D012189:Retrospective Studies; D015163:Superinfection / Q000453:epidemiology / Q000209:etiology / Q000382:microbiology
D000900:Anti-Bacterial Agents